| Next 10 |
BPMC News and Press, Blueprint Medicines Corporation
-
CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...
-
CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming inves...
-
CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webc...
-
Deciphera Pharmaceuticals (NASDAQ: DCPH) , a biopharmaceutical company based in Waltham, Mass., received a double shot of good news last week ... and has been climbing ever since. As of midday Friday, the biopharma's stock is now nearly $8 higher than it was at the end of the previous week -...
-
CytomX Stock Slumps on Disappointing Probody Data CytomX Therapeutics ( CTMX ) slumped as the company provided updates about its two lead drug candidates CX-072 and CX-2009. The company had also recently reported its financial results for the first quarter of 2020 and offered business upda...
-
Nasdaq has suspended trading in Deciphera Pharmaceuticals ( DCPH +6.6% ) pending the release of news. More news on: Deciphera Pharmaceuticals, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, Read more ...
-
Blueprint Medicines (NASDAQ: BPMC ) reports that it has received a Complete Response Letter (CRL) from the FDA regarding its marketing application for avapritinib in fourth-line gastrointestinal tumor (GIST). More news on: Blueprint Medicines Corporation, Bayer Aktiengesellschaft, Deciph...
-
CAMBRIDGE, Mass. , May 15, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has issued a co...
-
CAMBRIDGE, Mass. , May 14, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to present updated clinical data for pralsetinib in RET-al...
-
Blueprint Medicines ( BPMC +10.7% ) is poised for its best one-day gain in a month on the heels of a note from SVB Leerink on RET inhibitor pralsetinib (BLU-667). More news on: Blueprint Medicines Corporation, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, Read mo...
Stock Information
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
MENU
BPMC
BPMC Quote
BPMC Short
BPMC News
BPMC Articles
Get BPMC Alerts
News, Short Squeeze, Breakout and More Instantly...
-
CAMBRIDGE, Mass. , May 29, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW clinical trial of pralsetinib in pat...
-
CAMBRIDGE, Mass. , May 27, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the following upcoming inves...
-
CAMBRIDGE, Mass. , May 26, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conference call and webc...
Direct Branding and Market Awareness
